Trial Profile
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Alomfilimab (Primary) ; Atezolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Penile cancer; Renal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Kymab
- 13 Apr 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 10 Oct 2023 Planned End Date changed from 1 Nov 2024 to 1 Apr 2024.
- 10 Oct 2023 Planned primary completion date changed from 1 Nov 2024 to 1 Apr 2024.